UGA hopping: A sport for nephrologists too?

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2391-2395

  Torra, Roser ^a   Oliveira, Joao Paulo ^b   Ortiz, Alberto ^c,d,e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c 28400 Madrid   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e Section of Nephrology   (Spain)

Author keywords

aminoglycoside; ataluren; nonsense mutation; translational read through

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ATALUREN; CASPASE 12; GENTAMICIN; MESSENGER RNA; POLYPEPTIDE; OXADIAZOLE DERIVATIVE; STOP CODON;

ALPORT SYNDROME; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; FABRY DISEASE; FOLLOW UP; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; HETEROZYGOTE; HUMAN; KIDNEY POLYCYSTIC DISEASE; MEDULLARY SPONGE KIDNEY; NEPHROLOGIST; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; NOTE; PRIORITY JOURNAL; RIBOSOME; RNA TRANSLATION; SINGLE DRUG DOSE; STOP CODON; THERAPY EFFECT; URIC ACID NEPHROPATHY; VON HIPPEL LINDAU DISEASE; DRUG EFFECTS; GENETICS; KIDNEY DISEASES; PROTEIN SYNTHESIS;

AMINOGLYCOSIDES; CODON, NONSENSE; CODON, TERMINATOR; HUMANS; KIDNEY DISEASES; OXADIAZOLES; PROTEIN BIOSYNTHESIS;

EID: 77954806635     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq301     Document Type: Note

References (30)

1. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination co- dons in a mammalian translation system. RNA 2000; 6: 1044-1055
2. Nilsson M, Ryden-Aulin M. Glutamine is incorporated at the nonsense codons UAG and UAA in a suppressor-free Escherichia coli strain. Biochim Biophys Acta 2003; 1627: 1-6
3. Hu H, Gatti RA. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals. Curr Opin Allergy Clin Immunol 2008; 8: 540-546
4. Hyde SC, Gill DR. Ignoring the nonsense: a phase II trial in cystic fibrosis. Lancet 2008; 372: 691-692
5. Schmitz A, Famulok M. Chemical biology: ignore the nonsense. Nature 2007; 447: 42-43
6. Ishigaki Y, Li X, Serin G et al. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. Cell 2001; 106: 607-617
7. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 2007; 76: 51-74
8. McCaughan KK, Brown CM, Dalphin ME et al. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 1995; 92: 5431-5435
9. Namy O, Hatin I, Rousset JP. Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep 2001; 2: 787-793
10. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008; 24: 552-563
11. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-469
12. Wilschanski M, Yahav Y, Yaacov Yet al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-1441
13. Welch EM, Barton ER, Zhuo J et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91
14. Mendell JT, Sharifi NA, Meyers JL et al. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 2004; 36: 1073-1078
15. Hainrichson M, Nudelman I, Baasov T. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem 2008; 6: 227-239
16. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727
17. Du M, Liu X, Welch EM et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008; 105: 2064-2069
18. Hirawat S, Welch EM, Elfring GL et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47: 430-444
19. http://clinicaltrials.gov/ct2/results?term=PTC124 (24 December 2009, data last accessed)
20. Rossetti S, Consugar MB, Chapman AB et al. CRISP Consortium. Comprehensive molecular diagnostics in autosomal dominant poly- cystic kidney disease. J Am Soc Nephrol 2007; 18: 2143-2160
21. http://www.hgmd.cf.ac.uk/ac/index.php. (14 January 2010, date last accessed)
22. Denamur E, Delezoide AL, Alberti C et al. The Societe Franfaise de Foetopathologie. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int 2010; 77: 350-358
23. http://www.arup.utah.edu/database/ALPORT/ALPORT-display.php (30 March 2010, date last accessed)
24. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007; 18: 1547-1557
25. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human a-galactosidase. J Mol Biol 2004; 337: 319-335
26. Kerem E, Kerem B, Welch EM et al. PTC124 for cystic fibrosis. Lancet 2009; 373: 1426-1427
27. Saleh M, Vaillancourt JP, Graham RK et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429: 75-79
28. Peltz SW. Gunvalson and PTC Therapeutics' community outreach. Nat Biotechnol 2009; 27: 121-122
29. Allison M. Gunvalson decision sends shockwaves through industry. Nat Biotechnol 2008; 26: 1201-1202
30. van Deutekom JC, Janson AA, Ginjaar IB et al. Local dystrophin restoration with antisense oligonucleotide PR0051. N Engl J Med 2007; 357: 2677-2686